

## **ASX/MEDIA RELEASE**

4 May 2018

# **Class Action Update**

## Sydney, Australia

Sirtex Medical Limited (ASX:SRX)(**Sirtex**) today provides the following update to the market on the status of the class actions.

On 13 February 2017, Sirtex announced that a representative proceeding (as foreshadowed in its announcement on 30 January 2017) had been commenced against the company (**the First Proceeding**). On 19 December 2017, Sirtex announced that a second class action had been commenced against it in the Federal Court of Australia (**the Second Proceeding**).

On 30 April 2018, by orders of the Federal Court of Australia, the First Proceeding and the Second Proceeding were consolidated into a single proceeding. It is expected that the consolidated proceeding will be set down for hearing commencing sometime in April 2019.

#### - ENDS -

## About Sirtex Medical, www.sirtex.com

Sirtex Medical Limited (ASX:SRX) is an Australian based medical device company with global market coverage. Its core revenue producing technology, which has regulatory approvals, is a selective internal radiation therapy (SIRT), with clinically proven applications for liver cancer with over 86,000 doses supplied and administered at over 1,160 medical centres in more than 40 countries.

# **Investor Enquiries:**

Mr Darren Smith CFO & Company Secretary Sirtex Medical Limited Phone: +61 (0) 2 9964 8400

# **Investor/Media Enquiries:**

Dr Tom Duthy
Global Head of Investor Relations &
Corporate Development
Sirtex Medical Limited

Phone: +61 (0) 2 9964 8427 Email: tduthy@sirtex.com

To subscribe to our email alert service for ASX Announcements, please visit: http://www.sirtex.com/au/investors/email-alerts/

Follow us on Twitter: @sirtexmedical

Visit us on LinkedIn: Sirtex Medical Limited